Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutic (NQ: HALO )

52.05 -0.06 (-0.12%)
Streaming Delayed Price Updated: 1:13 PM EDT, Aug 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 645,432
Open 52.24
Bid (Size) 52.03 (4)
Ask (Size) 52.09 (1)
Prev. Close 52.11
Today's Range 51.83 - 53.22
52wk Range 32.83 - 57.09
Shares Outstanding 142,334,900
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NASDAQ:HALO is probably undervalued for the fundamentals it is displaying.
When you look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028! 
Via InvestorPlace

Performance

YTD
+39.19%
+39.19%
1 Month
-0.96%
-0.96%
3 Month
+27.37%
+27.37%
6 Month
+54.53%
+54.53%
1 Year
+23.89%
+23.89%

More News

Read More
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
Via Benzinga
Analyst Scoreboard: 14 Ratings For Halozyme Therapeutics
Via Benzinga
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
Via Investor's Business Daily
Beam Therapeutics Stock Earns RS Rating Jump To 85
Via Investor's Business Daily
Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective.
Via Chartmill
NASDAQ:HALO is showing good growth, while it is not too expensive.
Via Chartmill
What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
Via Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition
Via InvestorPlace
Biotech Arvinas Stock Earns 82 RS Rating
Via Investor's Business Daily
Denali Therapeutics Stock Gets Technical Rating Upgrade
Via Investor's Business Daily
3 Biotech Stocks to Buy Now: Q3 Edition
Via InvestorPlace
NASDAQ:HALO qualifies as a high growth stock and is consolidating.
Via Chartmill
NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
NASDAQ:HALO Shows Potential for a Breakout.
Via Chartmill
Decoding 12 Analyst Evaluations For Halozyme Therapeutics
Via Benzinga
NASDAQ:HALO: a strong growth stock preparing for the next leg up?.
Via Chartmill
3 Highly Rated Biotech Stocks for Your July Buy List
Via InvestorPlace
3 Breakout Biotech Stocks on Track to Double by 2032
Via InvestorPlace
UroGen Pharma Stock Earns 91 RS Rating
Via Investor's Business Daily
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval
Via Investor's Business Daily
Arcellx Stock Earns Relative Strength Rating Upgrade
Via Investor's Business Daily
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.